Peripheral Immunomarker Validation in Treatment-resistant Depression

CompletedOBSERVATIONAL
Enrollment

393

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

September 30, 2018

Study Completion Date

September 30, 2018

Conditions
Depressive Disorder, Major
Interventions
OTHER

MA

Monoaminergic antidepressant use

OTHER

DEP

Depression measured using the Hamilton Depression (HAM-D) questionnaire

Trial Locations (5)

Unknown

University of Sussex, Brighton

University of Cambridge, Cambridge

University of Glasgow, Glasgow

King's College London, London

University of Oxford, Oxford

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

University of Oxford

OTHER

collaborator

University of Glasgow

OTHER

collaborator

University of Sussex

OTHER

collaborator

King's College London

OTHER

collaborator

Janssen, LP

INDUSTRY

collaborator

H. Lundbeck A/S

INDUSTRY

collaborator

GlaxoSmithKline

INDUSTRY

lead

University of Cambridge

OTHER

NCT02752178 - Peripheral Immunomarker Validation in Treatment-resistant Depression | Biotech Hunter | Biotech Hunter